MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejrad.2021.110107

Медицинская библиотека · European journal of radiology · 2021

Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy.

Schweighofer-Zwink Gregor, Manafi-Farid Reyhaneh, Kölblinger Peter, Hehenwarter Lukas, Harsini Sara, Pirich Christian, Beheshti Mohsen

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: The 2-fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) is used for the evaluation of response to immunotherapy in malignant melanoma. Here, we evaluated the prognostic value of various metabolic parameters in baseline and different time points after therapy.

METHODS

In this retrospective study, 51 metastatic melanoma patients, who had received immunotherapy, were included. Patients with baseline and two follow-up 2-[18F]FDG PET/CT studies (3 and 6 months after therapy) were selected. Multiple metabolic parameters and tumor-to-background ratios (TBRs) were extracted and correlated with OS.

RESULTS

The 3- and 5-year OS rates were 49% and 43.1%, respectively. On baseline 2-[18F]FDG PET/CT, only standardized uptake value corrected for lean body mass (SULmax and SULpeak), as well as most of the TBRs were predictive for 3- and 5-year OS rates. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and most of the TBRs were predictive on both follow-up studies. Also, the changes in values of MTV, TLG and most of the TBRs from the baseline to the 3-month and 6- month follow-up studies were prognostic. On multivariate analysis, all of the most predictive parameters for OS were derived from the 3-month follow-up study. The ratio of TBRmean to the mediastinum was the best factor (cutoff value of 2.15, sensitivity of 88.5% and specificity of 68.0% for 3-year survival).

CONCLUSION

Metabolic parameters derived from 2-[18F]FDG PET/CT are valuable tools for the prediction of 3- and 5-year OS rates in metastatic melanoma patients undergoing immunotherapy. The 3-month follow-up 2-[18F]FDG PET/CT is of particular importance in this regard.

Для цитирования: Schweighofer-Zwink Gregor, Manafi-Farid Reyhaneh, Kölblinger Peter, Hehenwarter Lukas, Harsini Sara, Pirich Christian, Beheshti Mohsen. Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy.. European journal of radiology. 2021. DOI: 10.1016/j.ejrad.2021.110107.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.